Technology | March 23, 2015

AtriCure Launches CryoICE Cryo Ablation Probe for Treatment of Post-Thoracotomy Pain

System uses cryoanalgesia to freeze target tissue to treat cardiac arrhythmia

cryoICE, Atricure, ablation probe, cryoanalgesia, thoracotomy

CRYO2 image courtesy of AtriCure Inc.

March 23, 2015 — AtriCure Inc. announced that it has launched the availability of its cryoICE cryo ablation probe (CRYO2) to provide cryoanalgesia for temporary pain management. AtriCure’s cryoICE is the first U.S. Food and Drug Administration (FDA)-cleared cryo ablation probe for the treatment of cardiac arrhythmias and for the temporary ablation of peripheral nerves to block pain.

Cryoanalgesia is a method of temporarily relieving pain by cryo ablating the affected nerve, causing an interruption of pain impulses to the brain. For cardiac and thoracic surgery patients, the pain impulses are blocked by ablating the intercostal nerve bundle(s), thereby alleviating the pain associated with a thoracotomy incision. When applied appropriately, cryoanalgesia can relieve pain for several days and in some cases weeks.

AtriCure has a portfolio of products that include radiofrequency and cryo ablation devices that are used during cardiac surgery. The company’s cryoICE cryo ablation system has been indicated to freeze target tissue for the treatment of cardiac arrhythmias. The recently expanded indication for the cryoICE probe “for use in blocking pain by temporarily ablating peripheral nerves” provides surgeons with an additional option to treat post-thoracotomy pain.

“The pain management options available today are not optimal,” stated Andrea Trescot, M.D., past president of the American Society of Interventional Pain Physicians. “Cryoanalgesia has been studied for many years, and has been shown to successfully block pain with no long-term neural effects.”

Currently, surgeons use epidurals, intercostal nerve blocks and prescription narcotics for pain management. Studies have suggested that cryoanalgesia is a useful method for both short- and long-term relief from pain related to thoracotomy access. It is estimated that more than 25,000 cardiac and thoracic surgeries are performed in the United States every year using a thoracotomy approach.

“I have used cryoanalgesia as an adjunct to conventional pain relief techniques in nearly 75 cases of mitral valve surgeries via mini-thoracotomies,” stated Francis Shannon, M.D., cardiothoracic surgeon, Beaumont Health System. “I have been very impressed with the reduction in respiratory complications after surgery as well as narcotic requirements for chest pain.”

For more information: www.atricure.com

Related Content

Watchman FLX in Clinical Trial at MedStar Heart and Vascular Institute
News | Left Atrial Appendage (LAA) Occluders | June 26, 2018
MedStar Heart & Vascular Institute physicians participating in a clinical trial have become the first in the Mid-...
A slide image from Reddy's presntation at Heart Rhythm 2018, showing thrombus formation on the face of a Watchman LAA Occluder device in an echo image. #HRS2018

A slide image from Reddy's presntation at Heart Rhythm 2018, showing thrombus formation on the face of a Watchman device in an echo image.

Feature | Left Atrial Appendage (LAA) Occluders | May 18, 2018
May 18, 2018 — Left atrial appendage closure (LAAC) with the transcatheter Watchman device prevents thromboembolism f
AtriCure Launches AtriClip FLEX•V Device in the United States
Technology | Left Atrial Appendage (LAA) Occluders | February 22, 2018
February 22, 2018 — AtriCure Inc.
J&J Announces U.S. IDE Study to Evaluate Potential of New Device to Reduce Stroke Risk in Afib
News | Left Atrial Appendage (LAA) Occluders | January 18, 2018
January 18, 2018 – Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc., a worldwide
Videos | Left Atrial Appendage (LAA) Occluders | November 14, 2017
Vivek Reddy, M.D., director of cardiac arrhythmia services and professor of medicine, cardiology, Mount Sinai Hospita
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders | September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide
News | Left Atrial Appendage (LAA) Occluders | April 25, 2017
AtriCure Inc. announced it has sold more than 100,000 AtriClip Left Atrial Appendage Exclusion System devices worldwide...
atricure atriclip, LAA occlusion, acc17

The AtriCure Atriclip surgical LAA occlusion device. It loops over the LAA on the outside of the heart and clips it off from the rest of the heart to prevent the formation of clots.

Feature | Left Atrial Appendage (LAA) Occluders | March 29, 2017
March 29, 2017 — For patients with...
Aegis Medical Innovations, Sierra Ligation System, U.S. clinical trial, FDA approval, LAA occluder
Technology | Left Atrial Appendage (LAA) Occluders | March 22, 2017
Aegis Medical Innovations Inc. announced that it has received Investigational Device Exemption approval from the U.S....
Overlay Init